Please login to the form below

Not currently logged in

Micreos appoints chief medical officer

Dr Johan Frieling brings experience from Bayer and Genzyme

Micreos Dr Johan FrielingDutch biotech company Micreos has appointed Dr Johan Frieling as its new chief scientific officer.

In his new role Dr Frieling will be responsible for overseeing Micreos' antibiotic alternative, Staphefekt, as it begins clinical trials.

Mark Offerhaus, founder and chief executive officer of Micreos, said: “Johan has successfully developed a number of biopharmaceutical products up to FDA and EMA approval.

“For us he is the ideal person to lead Staphefekt to market in the new indications.”

Dr Frieling has over 20 years of clinical development experience and has previously held senior positions at Bayer, Genzyme and Pharmasquire Consultancy.

He joins Micreos from LFB Biotechnologies where he served most recently as director of global clinical research, with responsibility for all development products at the company.

Dr Freiling said: “It's a great time to be joining Micreos … I look forward to sharing my knowledge and leading the clinical development of Staphefekt, ultimately helping a large cohort of patients across the globe.”

23rd March 2016

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....
The Periodic Table of Healthcare Communications
The definitive framework for building healthcare communication strategies and plans. Covering Brand Planning, Customer Experience and Multi-channel Marketing....